Disposition and drug-drug interaction potential of veliparib (ABT-888), a novel and potent inhibitor of poly(ADP-ribose) polymerase

Drug Metabolism and Disposition

Volumn 39, Issue 7, 2011, Pages 1161-1169

  Li, Xiaofeng ^a   Delzer, Juergen ^b   Voorman, Richard ^a   De Morais, Sonia M ^a   Lao, Yanbin ^a  

^a ABBOTT LABORATORIES   (United States)

^b ABBOTT GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; AMINO ACID; BENZOIMIDAZOLE CARBOXAMIDE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DRUG METABOLITE; GLYCOPROTEIN P; LACTAM; N CARBAMOYL GLUCURONIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PYRROLIDINE DERIVATIVE; TRITIUM; UNCLASSIFIED DRUG; VELIPARIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG BILE LEVEL; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG INTERACTION; DRUG METABOLISM; DRUG OXIDATION; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TRANSFORMATION; DRUG TRANSPORT; DRUG URINE LEVEL; ENZYME ACTIVITY; ENZYME SUBSTRATE COMPLEX; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CELL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION;

ANIMALS; BENZIMIDAZOLES; DOGS; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; P-GLYCOPROTEIN; POLY(ADP-RIBOSE) POLYMERASES; RATS; RATS, SPRAGUE-DAWLEY; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION;

ANIMALIA; CANIS FAMILIARIS; RATTUS;

EID: 79959391542     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.037820     Document Type: Article

References (21)

1. American Cancer Society (2010) Cancer Facts and Figures 2010, American Cancer Society, Atlanta, GA.
2. de Groot MJ, Wakenhut F, Whitlock G, and Hyland R (2009) Understanding CYP2D6 interactions. Drug Discov Today 14:964-972.
3. Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, Bontcheva-Diaz VD, Cox BF, DeWeese TL, Dillehay LE, et al. (2007) ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 13:2728-2737. (Pubitemid 46795129)
4. Faessel HM, Burstein AH, Troutman MD, Willavize SA, Rohrbacher KD, and Clark DJ (2008) Lack of a pharmacokinetic interaction between a new smoking cessation therapy, varenicline, and digoxin in adult smokers. Eur J Clin Pharmacol 64:1101-1109.
5. Fan L, de Gooijer MC, Beumer JH, Christner SM, Beijnen JH, and van Tellingen O (2010) ABC transporters in the blood-brain barrier limit the brain penetration of the PARP inhibitor ABT-888. Proceedings of the AACR 101st Annual Meeting 2010; 2010 April 17-21; Washington, DC. Abstract LB-49. American Association for Cancer Research, Philadelphia, PA.
6. Feng B, Obach RS, Burstein AH, Clark DJ, de Morais SM, and Faessel HM (2008) Effect of human renal cationic transporter inhibition on the pharmacokinetics of varenicline, a new therapy for smoking cessation: an in vitro-in vivo study. Clin Pharmacol Ther 83:567-576. (Pubitemid 351417059)
7. Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR, Ji J, Monks A, Low JA, Chen A, et al. (2009) Phase 0 clinical trial of the poly(ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol 27:2705-2711.
8. Li J, Sha X, and LoRusso P (2009) Pharmacogenetics of a PARP inhibitor ABT-888 metabolic pathway. J Clin Oncol 27 (Suppl):Abstract e14556.
9. Marchetti S, Mazzanti R, Beijnen JH, and Schellens JH (2007) Concise review: clinical relevance of drug-drug and herb-drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist 12:927-941. (Pubitemid 47359135)
10. Molina JR, Northfelt DW, Erlichman C, Lensing JL, Luo Y, and Giranda V (2009) Ongoing phase 1 studies of a novel PARP inhibitor, ABT-888: pharmacokinetics, safety and anti-tumor activity. Proceedings of the AACR 100th Annual Meeting 2010; 2009 April 18-22; Denver, CO. Abstract 3602. American Association for Cancer Research, Philadelphia, PA.
11. Muscal JA, Thompson PA, Giranda VL, Dayton BD, Bauch J, Horton T, McGuffey L, Nuchtern JG, Dauser RC, Gibson BW, et al. (2010) Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates. Cancer Chemother Pharmacol 65:419-425.
12. 2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispos 34:121-130.
13. Palma JP, Wang YC, Rodriguez LE, Montgomery D, Ellis PA, Bukofzer G, Niquette A, Liu X, Shi Y, Lasko L, et al. (2009) ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin Cancer Res 15:7277-7290.
14. Papeo G, Forte B, Orsini P, Perrera C, Posteri H, Scolaro A, and Montagnoli A (2009) Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity? Expert Opin Ther Pat 19:1377-1400.
15. Penning TD (2010) Small-molecule PARP modulators - current status and future therapeutic potential. Curr Opin Drug Discov Devel 13:577-586.
16. Penning TD, Zhu GD, Gandhi VB, Gong J, Liu X, Shi Y, Klinghofer V, Johnson EF, Donawho CK, Frost DJ, et al. (2009) Discovery of the poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H- benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. J Med Chem 52:514-523.
17. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, and Poirier GG (2010) PARP inhibition: PARP1 and beyond. Nat Rev Cancer 10:293-301.
18. U.S. Food and Drug Administration (2006) Guidance for industry: drug interaction studies-study design, data analysis, and implications for dosing and labeling. U.S. Food and Drug Administration, Rockville, MD.
19. Vickers S and Polsky SL (2000) The biotransformation of nitrogen containing xenobiotics to lactams. Curr Drug Metab 1:357-389.
20. Wiegand R, Wu J, Sha X, LoRusso P, and Li J (2010) Simultaneous determination of ABT-888, a poly (ADP-ribose) polymerase inhibitor, and its metabolite in human plasma by liquid chromatography/tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 878:333-339.
21. Xu J, Kochanek KD, Murphy S, and Tejada-Vera B (2010) Deaths: final data for 2007. Natl Vital Stat Rep 58:1-136.